Evaxion Biotech Secures Nasdaq Compliance
Evaxion Biotech A/S (NASDAQ: EVAX) has received important news regarding its compliance status with Nasdaq's listing requirements. The company has successfully demonstrated that it meets the necessary stockholders’ equity requirement to remain listed. After a constructive dialogue with Nasdaq, Evaxion is proud to confirm its status as fully compliant, warding off any potential delisting determinations.
Strengthening Equity Position
Thanks to various capital market activities, Evaxion has effectively restored its equity above the minimum threshold. This achievement comes from a $10.8 million public offering completed recently, which served to bolster investor confidence in the company. Further enhancing its fiscal position, Evaxion utilized prefunded warrants and American Depositary Shares, contributing about $7.6 million to its equity. Collectively, these actions have infused approximately $17 million into the company, extending its cash runway to mid-2026.
Looking Ahead: Major Goals for 2025
As part of its ongoing strategy, the focus remains firmly on achieving critical milestones set for 2025. The leadership team recognizes the importance of sustaining investor support and continues its commitment to transparency and proactive communications. Christian Kanstrup, the CEO of Evaxion, expressed appreciation for Nasdaq's engagement throughout this process and emphasized the pivotal role of their strengthened equity and cash position in pursuing the company's goals.
Relationship with the European Investment Bank
Evaxion is also in discussions with the European Investment Bank (EIB) about the conversion of a €3.5 million out of a €7 million loan, which is predicted to further enhance the company’s equity position. This conversion is anticipated to occur in the first quarter of 2025, marking another significant financial improvement for Evaxion.
Implications of a Mandatory Panel Monitor
In accordance with Nasdaq regulations, the company has been placed under a Mandatory Panel Monitor following its recent compliance achievement. This monitor will last for one year. If Evaxion fails to maintain the minimum stockholders’ equity during this period, the company may receive a delisting determination without a chance to submit a new compliance plan for review. However, Evaxion remains committed to meeting all necessary standards to retain its listing.
About Evaxion Biotech
Based in Copenhagen, Evaxion Biotech is at the forefront of innovative healthcare solutions using its proprietary AI-Immunology™ platform. This cutting-edge approach utilizes artificial intelligence to decode the complexities of the human immune system, paving the way for developing personalized vaccines aimed at combatting cancer, bacterial diseases, and viral infections. The company’s commitment to transforming patient care is evident in its ongoing development of novel immunotherapies.
Contact Information for Inquiries
For those interested in learning more about Evaxion Biotech, you can reach out directly:
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
Frequently Asked Questions
What does Nasdaq's compliance confirmation mean for Evaxion?
The confirmation signifies that Evaxion has met the required stockholders’ equity expectations to maintain its listing on Nasdaq, thus avoiding delisting.
How has Evaxion strengthened its equity?
Evaxion successfully completed a $10.8 million public offering and utilized other capital market operations to reinforce its equity position.
What is the significance of the EIB loan conversion?
The conversion of the EIB loan is expected to increase Evaxion’s equity, which is crucial for its financial stability and strategic efforts.
What does the Mandatory Panel Monitor entail?
The monitor requires Evaxion to adhere to Nasdaq’s minimum equity requirement. If it fails to do so, the company may face delisting without a chance for recourse.
What is AI-Immunology™?
AI-Immunology™ is Evaxion Biotech's innovative platform that applies artificial intelligence to understand and utilize the human immune system in developing vaccines and treatments.
